Sermorelin vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | Exenatide |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |
What They Have in Common
Both Sermorelin and Exenatide are commonly used for: